Medidata Solutions Inc (NASDAQ:MDSO) Director Carlos Dominguez sold 9,066 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $66.85, for a total value of $606,062.10. Following the completion of the sale, the director now owns 66,020 shares of the company’s stock, valued at approximately $4,413,437. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Medidata Solutions Inc (NASDAQ MDSO) traded down $1.66 during midday trading on Friday, hitting $63.37. The stock had a trading volume of 539,800 shares, compared to its average volume of 394,226. The firm has a market cap of $3,801.72, a PE ratio of 90.53, a P/E/G ratio of 4.04 and a beta of 1.69. Medidata Solutions Inc has a one year low of $47.77 and a one year high of $85.92. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.29 and a quick ratio of 3.37.
Medidata Solutions (NASDAQ:MDSO) last released its earnings results on Thursday, October 26th. The company reported $0.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.02. The company had revenue of $140.08 million during the quarter, compared to analysts’ expectations of $141.27 million. Medidata Solutions had a return on equity of 11.54% and a net margin of 7.84%. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the firm earned $0.28 EPS. equities research analysts forecast that Medidata Solutions Inc will post 0.78 earnings per share for the current year.
MDSO has been the subject of a number of research reports. SunTrust Banks reiterated a “buy” rating and issued a $92.00 price objective on shares of Medidata Solutions in a research report on Friday, October 27th. Dougherty & Co upgraded Medidata Solutions from a “neutral” rating to a “buy” rating and set a $75.00 target price for the company in a research report on Monday, November 13th. Deutsche Bank initiated coverage on Medidata Solutions in a research report on Friday, December 8th. They set a “buy” rating and a $78.00 target price for the company. KeyCorp restated a “buy” rating and set a $86.00 target price on shares of Medidata Solutions in a research report on Sunday, September 17th. Finally, TheStreet downgraded Medidata Solutions from a “b” rating to a “c+” rating in a research report on Thursday, December 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Medidata Solutions has an average rating of “Buy” and a consensus price target of $84.54.
TRADEMARK VIOLATION WARNING: “Medidata Solutions Inc (MDSO) Director Sells $606,062.10 in Stock” was first published by Week Herald and is owned by of Week Herald. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://weekherald.com/2017/12/30/insider-selling-medidata-solutions-inc-mdso-director-sells-606062-10-in-stock.html.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.